跳至主要内容
临床试验/EUCTR2012-000619-10-NL
EUCTR2012-000619-10-NL进行中(未招募)不适用

Clinical proof-of-principle of the determination of the beta cell mass in vivo by SPECT imaging with the 111In-labeled GLP-1 analogue DTPA-[K40]-Exendin 4 - GLP-1 receptor targeting in diabetic and healthy individuals

Radboud University Nijmegen Medical Centre0 个研究点开始时间: 2012年6月19日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 21-60 years of age
  • Long-standing T1D (>5 years) or healthy volunteer with normal glucose tolerance
  • Body mass index (BMI) of 21-27
  • No previous treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors
  • No measurable C-peptide in T1D patients (stimulated)
  • Normal HbA1c (<7%) in healthy volunteers
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Age <21 or >60 years
  • T1D duration <5 years or pathologic glucose tolerance in healthy volunteers
  • BMI <21 or >27
  • Previous treatment with Exenatide or Dipeptidyl-Peptidase IV inhibitors
  • Measurable C-peptide in T1D patients
  • Elevated HbA1c values (>7%) in healthy volunteers

研究者

发起方
Radboud University Nijmegen Medical Centre

相似试验